First Quadrant’s Alexion Pharmaceuticals ALXN Stock Holding History

First Quadrant’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-6,909	Closed	-$620K	–	866
2020 Q1	$620K	Sell	6,909 -3,808	-36%	-$374K	0.09%	228
2019 Q4	$1.16M	Buy	10,717 +707	+7%	+$75.6K	0.1%	206
2019 Q3	$980K	Sell	10,010 -11,316	-53%	-$1.28M	0.09%	232
2019 Q2	$2.79M	Buy	21,326 +14,417	+209%	+$1.86M	0.19%	132
2019 Q1	$934K	Sell	6,909 -588	-8%	-$73.1K	0.07%	275
2018 Q4	$730K	Hold	7,497	–	–	0.06%	279
2018 Q3	$1.04M	Hold	7,497	–	–	0.02%	386
2018 Q2	$931K	Buy	7,497 +2,400	+47%	+$280K	0.02%	410
2018 Q1	$568K	Sell	5,097 -2,531	-33%	-$303K	0.01%	475
2017 Q4	$912K	Sell	7,628 -155,891	-95%	-$19M	0.02%	453
2017 Q3	$22.9M	Sell	163,519 -7,927	-5%	-$1.08M	0.44%	63
2017 Q2	$20.9M	Buy	+171,446	New	+$20M	0.42%	72
2015 Q2	–	Sell	-149,000	Closed	-$25.8M	–	816
2015 Q1	$25.8M	Buy	149,000 +148,000	+14,800%	+$26.8M	0.54%	57
2014 Q4	$185K	Buy	+1,000	New	+$185K	﹤0.01%	536
2014 Q3	–	Sell	-13,676	Closed	-$2.14M	–	849
2014 Q2	$2.14M	Sell	13,676 -77,000	-85%	-$12.2M	0.05%	303
2014 Q1	$13.8M	Buy	90,676 +43,600	+93%	+$6.93M	0.31%	100
2013 Q4	$6.26M	Hold	47,076	–	–	0.15%	172
2013 Q3	$5.47M	Buy	+47,076	New	+$5.16M	0.14%	183

Other funds holding ALXN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

First Quadrant's ALXN Position: Q2 2020 in Review

First Quadrant sold out of Alexion Pharmaceuticals (ALXN) in Q2 2020, closing a stake of 6,909 shares — an estimated $620K sold.

First Quadrant first reported a position in ALXN in Q3 2013 and held it in 18 quarters. The position peaked at $25.8M in Q1 2015. 707 funds tracked by Wall St. Rank hold ALXN as of Q2 2020.

First Quadrant reported no remaining Alexion Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
First Quadrant sold 6,909 Alexion Pharmaceuticals shares in Q2 2020, an estimated $620K.
First Quadrant first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 18 quarters.
First Quadrant's Alexion Pharmaceuticals position peaked at $25.8M in Q1 2015.
707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2020.

Based on First Quadrant's 13F filing for Q2 2020, filed 28 Jul 2020.